Castle Biosciences (CSTL) CEO Maetzold sells 4,017 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Castle Biosciences president and CEO Derek J. Maetzold sold 4,017 shares of common stock in early February 2026 under a pre-arranged Rule 10b5-1 trading plan. Sales included 3,200 shares on February 3 at a weighted-average price of $39.913 and two sales on February 4 totaling 817 shares at weighted-average prices of $37.822 and $38.61. After these transactions, he directly held 83,698 common shares. He also reported indirect beneficial ownership of additional Castle Biosciences shares through multiple family and grantor retained annuity trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 4,017 shares ($158,757)
Net Sell
12 txns
Insider
MAETZOLD DEREK J
Role
Pres. & Chief Exec. Officer
Sold
4,017 shs ($159K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 646 | $37.822 | $24K |
| Sale | Common Stock | 171 | $38.61 | $7K |
| Sale | Common Stock | 3,200 | $39.913 | $128K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 83,869 shares (Direct);
Common Stock — 52,923 shares (Indirect, By The Maetzold Descendants 2020 Trust)
Footnotes (1)
- These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 8, 2025. This transaction was executed in multiple trades at prices ranging from $39.590 to $40.360, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $37.490 to $38.080, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $38.520 to $38.885, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries. Held by Derek Maetzold 2020 Irrevocable Trust of which the Reporting Person is the trustee and his children are beneficiaries. Held by The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO John Derek Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold of which the Reporting Person is the trustee and his child is the beneficiary. Held by DJM Grantor Retained Annuity Trust No. 5 of which the Reporting Person is the trustee and beneficiary. Held by DJM Grantor Retained Annuity Trust No. 6 of which the Reporting Person is the trustee and the beneficiaries are The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold and The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold. Held by DJM Grantor Retained Annuity Trust No. 7 of which the Reporting Person is the trustee and beneficiary.
FAQ
Was Derek Maetzold’s February 2026 CSTL stock sale under a Rule 10b5-1 plan?
Yes. The filing states the transactions were made under a Rule 10b5-1 trading plan adopted on May 8, 2025. Such preset plans allow insiders to schedule trades in advance, helping separate personal trading decisions from later company-specific news.
What role does Derek Maetzold hold at Castle Biosciences (CSTL)?
Derek J. Maetzold is identified as president, chief executive officer, and a director of Castle Biosciences. His Form 4 filing reflects transactions and holdings in company common stock associated with his status as an executive officer and board member.